Clinical Trial Search

Primary: Percentage of Participants With at Least a 1-Grade Increase (Improvement) From Baseline in the Investigator's Assessment of Overall Eyelash Prominence (GEA) — 82.4…

Primary: Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale — 83.9; 77.1; 43.0 percentage of…

Primary: Percentage of Subjects Satisfied With Latisse® — 92.48 Percentage of Subjects

Primary: Percentage of Treatment Responders at Month 4 — 39.3; 10.9 Percentage of Subjects

Primary: Percentage of Participants With Adverse Events — 35.4; 43.5 Percentage of participants

Primary: Percentage of Treatment Responders in Overall Eyelash Prominence at Month 4 — 69.6; 48.8 Percentage of Patients

Primary: Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA) — 77.3; 17.6 Percentage of…

Primary: Percentage of Participants With at Least a 1-Grade Increase in Overall Eyelash Prominence Using the Global Eyelash Assessment Scale (GEA) — 88.9; 27.8 Percentage of…

Primary: Change From Baseline in Eyelash Length at Month 3 — 5.65; 5.68; 5.95; 0.74 millimeters (mm)

Primary: Eyelash Length as Measured by Digital Image Analysis (DIA) — 7.33 Millimeters (mm)

Primary: Percentage of Participants Experiencing at Least a 1-grade Increase on the Global Eyelash Assessment (GEA) Scale From Baseline to Week 16 — 5.1; 2.1; 14.6; 7.8…

Primary: Efficacy of Bimatoprost in Lengthening of Eyelashes — 2; 1.1 mm

Primary: Graded Change in Dermatochalasis — .2679 units on a scale

Primary: Percent Change in Target Area Total Hair Count — -2.6; 27.4; 4.9; -5.8 percentage change in total hair count

Primary: Percentage of Participants Who Are Satisfied or Very Satisfied With Their Eyelashes Overall — 67.4; 7.1 Percentage of participants

Primary: Change From Baseline in Target Area Hair Count (TAHC) — 153.1; 161.1; 145.2; 163.0 terminal hairs/cm^2

Primary: Clinician's Eyebrow Assessment — 0 score on a scale

Primary: Change From Baseline in Eyelash Length at Week 20 — 5.92; 1.10 Millimeter (mm)

Primary: Percentage of Subjects With Treatment-Emergent Adverse Events [Safety and Tolerability]) — 0; 0; 0 Participants

Primary: Change From Baseline in Target Area Hair Count (TAHC) — 135.0; 145.7; 151.5; 143.7 terminal hairs/cm^2

Primary: Tear Break up Time — 0.0; 2.9 seconds

Primary: Humphrey Visual Field — 9.8; 12.1; 11.1; 16.1 Points seen

Primary: Maximum Plasma Level (Cmax) Following a Single Dose of Bimatoprost — 0.552; 1.77; 5.58 Picograms/Milliliter (pg/mL)

Primary: Change From Baseline in Nail Length of Hands — 13.49; 15.10; 1.34; 1.51 mm — p=0.532

Primary: Interpalpebral Fissure (IPF) During Spontaneous Blink — 2.4; 4.1; 1.1 millimeters — p=<0.001

Primary: Number of Participants With a Response Defined as IGA-C (Investigators Global Assessment) Score ≤ 2 and a SSA-C (Subject Self-Assessment) Score ≤ 2 — 2; 3; 4; 2…

Primary: Mean Change in Number of Points Seen on the Leicester Peripheral Field Test (LPFT) in RVL-1201 Group vs. Vehicle Group — 5.2; 1.5; 6.4; 2.2 Points seen — p=<0.0001

Primary: Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 — 3; 1…

Primary: Lower Eyelid Steatoblepharon Severity (LESS) Score--Clinician-Reported — 27; 6 participants — p=0.020

Primary: The Extent of Latanoprost, Bimatoprost and Travoprost Induced Periocular Skin Hyperpigmentation Over a One Year Time Course in Newly Diagnosed Primary Open Angle and…